HUB Organoids in Financial Times

December 10, 2019. Yesterday the Financial Times featured an article on Organoid Innovation:

Organoid innovation offers potential for cancer research.

“Organoids have become one of the fastest growing fields in biomedical research over the past decade”

Prof Clevers: “We set up a non-profit foundation called Hubrecht Organoid Technology [HUB], which holds my lab’s patents. In addition to carrying out research, HUB offers licences for drug screening and access to organoids in its biobanks for pre-clinical drug discovery and validation.”

Pharmaceutical companies are using organoids derived from specific tumours to screen potential cancer drugs. A wide range of tissues are available for applications ranging from drug discovery to personalised medicine.

May 27, 2020 Studying the development of ovarian cancer wi... Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of hig... read more
May 26, 2020 HUB Patient-Derived Organoids added to CrownB... San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform w... read more
May 13, 2020 Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species o... read more